Serum NfL and GFAP levels were higher in NMOSD patients than MS patients; after adjusting for important clinical variables that may affect biomarker levels (age, EDSS score, days from the last attack to blood sampling, recent relapse <60 days), only GFAP levels remained significantly elevated in NMOSD patients. Here, GFAP is linked to myeloid sarcoma.